Wang Haiyan,Cao Jianfeng,Fu Liping,Xiang Liangcheng,Tian Tao,Wang Jixiang,Shi Ming,Li Xiaojun,Tang Chunguang,Efficacy observation of clinical medication guided by genetic testing of antipsychotic drugs in patients with schizophrenia[J].SICHUAN MENTAL HEALTH,2024,37(5):420-426
Efficacy observation of clinical medication guided by genetic testing of antipsychotic drugs in patients with schizophrenia
DOI:10.11886/scjsws20240226005
English keywords:Drug genetic testing  Schizophrenia  Clinical efficacy  Medication compliance  Social function
Fund projects:达州市2019年市级医学科研立项课题(项目名称:抗精神病药物基因检测指导临床用药的疗效观察,项目编号:2019033)
Author NameAffiliationPostcode
Wang Haiyan Dazhou Minkang Hospital Dazhou 635000 China 635000
Cao Jianfeng Dazhou Minkang Hospital Dazhou 635000 China 635000
Fu Liping Dazhou Minkang Hospital Dazhou 635000 China 635000
Xiang Liangcheng West China Second University Hospital Sichuan University Chengdu 610041 China 610041
Tian Tao Ning'an Hospital of Ningxia Hui Autonomous Region Yinchuan 750000 China 750000
Wang Jixiang Dazhou Minkang Hospital Dazhou 635000 China 635000
Shi Ming Dazhou Minkang Hospital Dazhou 635000 China 635000
Li Xiaojun Dazhou Minkang Hospital Dazhou 635000 China 635000
Tang Chunguang* Dazhou Minkang Hospital Dazhou 635000 China 635000
Hits:
Download times:
English abstract:
      Background Results of genetic testing for antipsychotic drugs can guide the rational use of drugs in clinical practice and help improve the clinical symptoms of patients with schizophrenia. However, there is currently limited evidence in China regarding the impact of genetic testing results on medication adherence, social function and drug side effects of antipsychotic drug treatment.Objective To explore the improvement of clinical symptoms, medication adherence and social function in patients with schizophrenia under the guidance of antipsychotic drug gene testing results and examine the safety of drug treatment, so as to provide references for ifor precise treatment of schizophrenia patients.Methods Patients with acute schizophrenia who received hospitalization at Dazhou Minkang Hospital from July 2019 to August 2021 as well as met the diagnostic criteria of the International Classification of Diseases, tenth edition (ICD-10) were selected as research subjects (n=144). Based on random number table, subjects were divided into study group and control group, with 72 cases in each group. Control group received drug treatment based on the doctor's clinical experience, while study group received drug treatment based on the results of gene testing for antipsychotic drug. Both treatments lasted for 12 weeks. At baseline as well as 2, 4, 8 and 12 weeks after treatment, Positive and Negative Syndrome Scale (PANSS), 8-item Morisky Medication Adherence Scale (MMAS-8), Social Functional Rating Scale (SFRS) and Treatment Emergent Symptom Scale (TESS) were adopted for assessment.Result Time effect and group effect of the reducing rate of PANSS, MMAS-8 and SFRS scores in the groups were statistically significant (Ftime=95.251, 6.650, 14.101, Fgroup=38.055, 58.175, 128.221, P<0.01). The interaction effect of the reduction rates of MMAS-8 scores in two groups was statistically significant (Finteraction=5.837, P<0.01). The group effect and interaction effect of the severity scores of drug side effects and patient pain scores in two groups were statistically significant (Fgroup=7.553, 81.533, Finteraction=8.693, 9.322, P<0.01).Conclusion In terms of improving clinical symptom relief, medication adherence, social function and drug side effects, medication for patients with schizophrenia guided by genetic testing of antipsychotic drugs may be more effective than that relying on medication based on clinical experience. [Funded by 2019 Dazhou City Municipal Medical Research Project (number, 2019033)]
View Full Text   View/Add Comment  Download reader
Close